Barriere G, Pelloquin-Mvogo Z, Boulain M, Khsime I, Bharatiya R, Riquier M
Int J Mol Sci. 2025; 26(5).
PMID: 40076918
PMC: 11901079.
DOI: 10.3390/ijms26052298.
Lipari N, Galfano A, Venkatesh S, Grezenko H, Sandoval I, Manfredsson F
Front Neural Circuits. 2024; 18:1463941.
PMID: 39634948
PMC: 11615880.
DOI: 10.3389/fncir.2024.1463941.
Lorenc-Koci E, Kaminska K, Lenda T, Konieczny J
Molecules. 2024; 29(18).
PMID: 39339313
PMC: 11434559.
DOI: 10.3390/molecules29184318.
Buchanan A, Mena S, Choukari I, Vasa A, Crawford J, Fadel J
Mol Med. 2024; 30(1):33.
PMID: 38429661
PMC: 10908133.
DOI: 10.1186/s10020-023-00773-9.
Pogorelov V, Martini M, Jin J, Wetsel W, Caron M
Biomolecules. 2023; 13(11).
PMID: 38002340
PMC: 10669682.
DOI: 10.3390/biom13111658.
Limiting Monoamines Degradation Increases L-DOPA Pro-Locomotor Action in Newborn Rats.
Khsime I, Boulain M, Fettah A, Chagraoui A, Courtand G, De Deurwaerdere P
Int J Mol Sci. 2023; 24(19).
PMID: 37834195
PMC: 10572489.
DOI: 10.3390/ijms241914747.
Levodopa-Induced Dyskinesias in Parkinson's Disease: An Overview on Pathophysiology, Clinical Manifestations, Therapy Management Strategies and Future Directions.
di Biase L, Pecoraro P, Carbone S, Caminiti M, Di Lazzaro V
J Clin Med. 2023; 12(13).
PMID: 37445461
PMC: 10342913.
DOI: 10.3390/jcm12134427.
Axon terminal hypertrophy of striatal projection neurons with levodopa-induced dyskinesia priming.
Nakamura T, Nishijima H, Mori F, Kinoshita I, Kon T, Suzuki C
Front Neurosci. 2023; 17:1169336.
PMID: 37351424
PMC: 10282195.
DOI: 10.3389/fnins.2023.1169336.
The muscarinic M4 acetylcholine receptor exacerbates symptoms of movement disorders.
Chambers N, Millett M, Moehle M
Biochem Soc Trans. 2023; 51(2):691-702.
PMID: 37013974
PMC: 10212540.
DOI: 10.1042/BST20220525.
Broad Serotonergic Actions of Vortioxetine as a Promising Avenue for the Treatment of L-DOPA-Induced Dyskinesia.
Budrow C, Elder K, Coyle M, Centner A, Lipari N, Cohen S
Cells. 2023; 12(6).
PMID: 36980178
PMC: 10047495.
DOI: 10.3390/cells12060837.
The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson's disease.
Nagatsu T, Nakashima A, Watanabe H, Ito S, Wakamatsu K, Zucca F
J Neural Transm (Vienna). 2023; 130(5):611-625.
PMID: 36939908
PMC: 10121510.
DOI: 10.1007/s00702-023-02617-6.
Behavioral and neurochemical interactions of the tricyclic antidepressant drug desipramine with L-DOPA in 6-OHDA-lesioned rats. Implications for motor and psychiatric functions in Parkinson's disease.
Kaminska K, Lenda T, Konieczny J, Lorenc-Koci E
Psychopharmacology (Berl). 2022; 239(11):3633-3656.
PMID: 36178508
PMC: 9584871.
DOI: 10.1007/s00213-022-06238-x.
The effects of Vilazodone, YL-0919 and Vortioxetine in hemiparkinsonian rats.
Smith S, Sergio J, Coyle M, Elder K, Centner A, Cohen S
Psychopharmacology (Berl). 2022; 239(7):2119-2132.
PMID: 35275226
DOI: 10.1007/s00213-022-06078-9.
Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson's Disease.
Chagraoui A, Di Giovanni G, De Deurwaerdere P
Biomolecules. 2022; 12(2).
PMID: 35204744
PMC: 8961531.
DOI: 10.3390/biom12020243.
Role of 5-HT1A Receptor in Vilazodone-Mediated Suppression of L-DOPA-Induced Dyskinesia and Increased Responsiveness to Cortical Input in Striatal Medium Spiny Neurons in an Animal Model of Parkinson's Disease.
Altwal F, Padovan-Neto F, Ritger A, Steiner H, West A
Molecules. 2021; 26(19).
PMID: 34641332
PMC: 8510243.
DOI: 10.3390/molecules26195790.
Optimizing the selection of Parkinson's disease patients for neuromodulation using the levodopa challenge test.
Kulshreshtha D, Pieterman M, Gilmore G, Jog M
J Neurol. 2021; 269(2):846-852.
PMID: 34191078
DOI: 10.1007/s00415-021-10666-8.
Postmortem Studies of Fetal Grafts in Parkinson's Disease: What Lessons Have We Learned?.
Li J, Li W
Front Cell Dev Biol. 2021; 9:666675.
PMID: 34055800
PMC: 8155361.
DOI: 10.3389/fcell.2021.666675.
Effects of Aging on Levo-Dihydroxyphenylalanine- Induced Dyskinesia in a Rat Model of Parkinson's Disease.
Nishijima H, Kimura T, Mori F, Wakabayashi K, Kinoshita I, Nakamura T
Front Aging Neurosci. 2021; 13:650350.
PMID: 34054505
PMC: 8155371.
DOI: 10.3389/fnagi.2021.650350.
Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA-induced dyskinesia.
Fridjonsdottir E, Shariatgorji R, Nilsson A, Vallianatou T, Odell L, Schembri L
Sci Adv. 2021; 7(2).
PMID: 33523980
PMC: 7787486.
DOI: 10.1126/sciadv.abe5948.
The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson's Disease.
Altwal F, Moon C, West A, Steiner H
Cells. 2020; 9(10).
PMID: 33050305
PMC: 7600385.
DOI: 10.3390/cells9102265.